Patients with metastatic NSCLC expressing PD-L1 ≥ 50% may be treated with either ICI monotherapy or chemoimmunotherapy, but there have been no prospective comparisons between these two strategies with respect to other biomarkers [9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.